Emerging Data and Clinical Advances in MS:

Slides:

Advertisements

Similar presentations

© 2014 Direct One Communications, Inc. All rights reserved. 1 Controversies in the Treatment of Multiple Sclerosis Sara S. Qureshi, MD The University of.

Advertisements

© 2014 Direct One Communications, Inc. All rights reserved. 1 A New Era of Therapy in Multiple Sclerosis: Balancing the Options and Challenges Ahead Jennifer.

Multiple Scleroris Lyle Wiemerslage, PhD.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Highlights From the 2015 European Multiple Sclerosis Meeting

Highlights From the 2017 Annual European MS Meeting

Current Dyslipidemia Management Guidelines Residual Risk.

Why New Treatments for Schizophrenia Should Be on Your Radar

Renal Denervation Two Late-Breaking Clinical Trials.

MS Highlights From the 2017 Annual Neurology Meeting

MR Imaging in Children.

Program Goals Teriflunomide: Pooled Safety Data.

Thrombosis, Cancer, and NOACs

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

The ABCs of AF.

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow

New Challenges Facing Multiple Sclerosis Nurses

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Optimizing Outcomes in the Management of GIST

T-Cell Directed Therapy in MS

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Challenges in Managing Progressive Multiple Sclerosis

Addressing Disease Burden in Asthma

How Can we Improve Outcomes for the Elderly Patient with AML?

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Dispelling Myths and Misconceptions ACC/AHA 2013 Digoxin Guidelines for Heart Failure.

Are We Closer to Personalized Medicine in MS?

More Than Meets the Eye.

What Is the Role of Injectables in the Modern Era of MS Treatment?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advancing Acute Coronary Syndrome Assessment:

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Charting Progress in MS Treatment:

Personalized Therapy in Relapsed or Refractory CLL

Treating to Target in MS

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Using Heart Rate as a Biomarker in Clinical Practice.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Identifying High-Risk AF Patients

Program Goals Overview Is NEDA a Reasonable Target?

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Advancing Patient Care in RA

Tackling Schizophrenia With Your Patients

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Clinical Challenges and Updates in Managing Seizure Clusters

The ABCs of AF.

Individualizing Therapy for RA: Are We There Yet?

Renal Function and Myeloma Therapeutics

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Novel Therapeutics in MS

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

My PAH Patient.

Uncovering the Right Sequence

Presentation transcript:

Emerging Data and Clinical Advances in MS:

Goals

Disclaimers

Speaker: Stephen Krieger, MD

CombiRx: Relapse Activity

CombiRx: MRI Outcomes

Teriflunomide: TOWER Study

Daclizumab: SELECTION Trial

Speaker: Robert C. Bermel, MD

Vitamin D Status in Optic Neuritis

Microcystic Macular Edema

Biomarkers - Antibodies

Biomarkers - MRI

Speaker: Amy Perrin Ross, APRN, MSN

Pregnancy Outcomes: Teriflunomide

Teriflunomide in Men

Interferon β-1a Registry

Natalizumab Registry

Other Agents

Counseling Patients

Predicting Adherence

Key Points

Speaker: Timothy L. Vollmer, MD

Cognitive Reserve

Cognition in MS

Cognitive Issues in Children

Cognitive Dysfunction and MRI

Cognition in MS: Other Issues

Looking Ahead

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)